Literature DB >> 9050373

The function of BCR/ABL and related proto-oncogenes.

A Gotoh1, H E Broxmeyer.   

Abstract

The BCR/ABL oncogene product is one of the genes associated with and possibly responsible for human leukemias. Chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia are associated with p210BCR/ABL and p185BCR/ABL, respectively. Abelson murine leukemia virus encodes the related oncogene product, v-Abl, and also causes pre-B-cell leukemia. In this article, recent advances in understanding the function of these oncogenes as well as the function of normal counterparts, c-Abl and Bcr, are discussed. Intracellular signaling events initiated from these oncogene products are emphasized. The possibilities are also discussed that inhibition of apoptosis and altered adhesive properties to the bone marrow microenvironment by BCR/ABL might contribute to disease initiation.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9050373     DOI： 10.1097/00062752-199704010-00002

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN： 1065-6251            Impact factor:   3.284


  11 in total

Review 1.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

2.  Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-Abl.

Authors:  Philippe Soubeyran; Ana Barac; Iwona Szymkiewicz; Ivan Dikic
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

3.  BCR/ABL inhibition by an escort/phosphatase fusion protein.

Authors:  Y M Lim; S Wong; G Lau; O N Witte; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

4.  Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway.

Authors:  Z Dai; R C Quackenbush; K D Courtney; M Grove; D Cortez; G W Reuther; A M Pendergast
Journal:  Genes Dev       Date:  1998-05-15       Impact factor: 11.361

5.  Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.

Authors:  Akihiko Gotoh; Keisuke Miyazawa; Yoshiko Uchida; Goro Sashida; Ken Kawakubo; Yuzuru Kuriyama; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

6.  Hypocellular Philadelphia chromosome-positive mixed-phenotype acute leukemia successfully treated with dasatinib: A case report.

Authors:  Shin Lee; Kei Fujita; Hiroto Wakayama; Yusuke Kito; Takeshi Hara; Hisashi Tsurumi
Journal:  Mol Clin Oncol       Date:  2021-12-14

7.  Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.

Authors:  Huan-Chau Lin; Ferry Saputra; Gilbert Audira; Yu-Heng Lai; Marri Jmelou M Roldan; Honeymae C Alos; Charlaine A Aventurado; Ross D Vasquez; Guan-Jhe Tsai; Ken-Hong Lim; Chung-Der Hsiao
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

8.  GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription.

Authors:  Yuan-Yeh Kuo; Zee-Fen Chang
Journal:  Mol Cell Biol       Date:  2007-04-09       Impact factor: 4.272

9.  Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.

Authors:  M Horita; E J Andreu; A Benito; C Arbona; C Sanz; I Benet; F Prosper; J L Fernandez-Luna
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

10.  A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

Authors:  Kara J Johnson; Ian J Griswold; Thomas O'Hare; Amie S Corbin; Marc Loriaux; Michael W Deininger; Brian J Druker
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.